100 mg/dL, and in Patients Already

Primary Composite Endpoint

All Patients

On maximum intensity statin

On less intense statin

0.4
Secondary Composite Endpoint

All Patients
On maximum intensity statin

On less intense statin

•

I

0

I

I
1.0

I

•

I

I I I
---

I

-fr

I

I

HR (95°/o Cl)

0.85 (0.79-0.92)
0.86 (0.75-0.98)

0.85 (0.78-0.93)

2.5

0.80 (0.73-0.88)
0.78 (0.66-0.92)

0.81 (0.72-0.90)

Pinteraction

0.88

0.71

OA 1D 2.5

Evolocumab better Placebo better

Directory: bitstream -> 10044
bitstream -> Present state of the area
10044 -> A new Method to Determine Dispersive Surface Energy Site Distributions by Inverse Gas Chromatography
10044 -> A case study of japanese language teaching
10044 -> Palaeomagnetic evidence for the persistence or recurrence of geomagnetic main field anomalies in the South Atlantic
10044 -> Blair W. McPhee, a, b, c
10044 -> Inattention blindness in surgery
10044 -> Archie Hughes-Hallett, mrcs
10044 -> Intraoperative ultrasound overlay in robot assisted partial nephrectomy
10044 -> Micronutrient supplementation augments anti-mycobacterial immune responses in tst reactive household contacts
10044 -> Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy 2